MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate

British Journal of Cancer

Volumn 91, Issue 12, 2004, Pages 2086-2093

  Qu, C F ^a,b   Li, Y ^a   Song, Y J ^a,b   Rizvi, S M A ^a   Raja, C ^a   Zhang, D ^a   Samra, J ^c,d   Smith, R ^c,d   Perkins, A C ^e   Apostolidis, C ^f   Allen, B J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f JOINT RESEARCH CENTRE   (Italy)

Author keywords

C595 monoclonal antibody; MUC 1 mucin; Pancreatic cancer cell lines; Pancreatic tumours; Radioimmunoconjugate; particle emitter 213Bi

Indexed keywords

ANTIBODY CONJUGATE; BISMUTH 213; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595; MUCIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL ASSAY; CELL SPECIFICITY; CELL SURFACE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; NICK END LABELING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION RESPONSE; TARGET CELL;

EID: 19944430969     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602232     Document Type: Article

References (31)

1. Abbas Rizvi SM, Sarkar S, Goozee G, Allen BJ (2000) Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res 10:281-289
2. Allen BJ (1999) Can alpha-immunotherapy succeed where other systemic modalities have failed? Nucl Med Commun 20: 205-207
3. 213Bi. Radiochimica Acta 79: 145-149
4. Farah RA, Clinchy B, Herrera L, Vitetta ES (1998) The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukar Gene Expr 8: 321-356
5. Feng H, Ghazizadeh M, Konishi H, Araki T (2002) Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 32: 525-529
6. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501
7. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823
8. Hall EJ (1994) Molecular biology in radiation therapy: the potential impact of recombinant technology on clinical practice. Int J Radiat Oncol, Biol, Phys 30(5): 1019-1028
9. Hughes OD, Bishop MC, Perkins AC, Frier M, Price MR, Denton G, Smith A, Rutherford R, Schubiger PA (1997) Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Eur J Nucl Med 24: 439-443
10. Hughes OD, Bishop MC, Perkins AC, Wastie ML, Denton G, Price MR, Frier M, Renley H, Rutherford R, Schubiger PA (2000a) Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol 18: 363-370
11. Hughes OD, Denley H, Kunker RB (2000b) MUC1 mucin expression in transitional cell carcinoma of the bladder. J of Urol Paththol 12: 179-191
12. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Harnacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100: 1233-1239
13. Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S (1999) Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi. Br J Cancer 80: 175-184
14. Kitamura H, Yonezawa S, Tanaka S, Kim YS, Sato E (1996) Expression of mucin carbohydrates and core proteins in carcinomas of the ampulla of Vater: their relationship to prognosis. Jpn J Cancer Res 87: 631-640
15. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999 (comment). Ca: a Cancer J Clin 49: 8-31, 1
16. Li Y, Tian Z, Rizvi S, Bander NH, Allen BJ (2002) In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostat Dis 5: 36-46
17. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL (1992) Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat Res 130: 220-226
18. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings Jr MW, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA (2000) An alpha-particle emitting antibody. Cancer Res 60: 6095-6100
19. McDevitt MR, Scheinberg DA (2002) Ac-225 and her daughters: the many faces of Shiva. Cell Death Differ 9: 593-594
20. Mommers EC, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J, Meijer CJ, Baak JP, van Diest PJ (1999) Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. Int J Cancer 84: 466-469
21. Murray A, Simms MS, Scholfield DP, Vincent RM, Denton G, Bishop MC, Price MR, Perkins AC (2001) Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J Nucl Med 42: 726-732
22. Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, Symonds IM, Clarke AJ, Chan WC, Baldwin RW (1990) C595 - a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 61: 681-686
23. Ren J, Li Y, Kufe D (2002) Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 277: 17616-17622
24. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA (2000) Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 88: 507-518
25. Scheinberg DA, Strand M, Gansow OA (1982) Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science 215: 1511-1513
26. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985-1995, using the National Cancer Database (comment). J Am College of Surg 189: 1-7
27. Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA (1999) Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 40:1935-1946
28. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS, Sato E (1998) Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 4: 2605-2614
29. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J, Figdor CG (1993) Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151: 767-776
30. Vaughan AT, Bateman WJ, Fisher DR (1982) The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system. Int J Radiat Oncol, Biol, Phys 8: 1943-1946
31. Zotter S, Hageman PC, Lossnitzer A, van den Tweel J, Hilkens J, Mooi WJ, Hilgers J (1988) Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland. Int J Cancer Suppl 3: 38-44